Adverse Events from Chemotherapy in Patients with Hematologic Malignancies at the Second Male Medical Ward at Songklanagarind Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To determine incidence of adverse events from chemotherapy in patients with hematologic malignancies. Method: The study was a descriptive study collecting the data from all patients receiving chemotherapy for hematologic malignancies in the second male medical ward at Songklanagarind Hospital during October 2013-December 2014. The pharmacists assessed the severity of adverse events using CTCAE version 4.0. Results: All 35 participants experienced 90 adverse events from chemotherapies. The most common regimen was Hyper CVAD (34.28%). Adverse events identified in the study included hematologic disorders (74%), electrolyte imbalance (14%), gastrointestinal symptoms (7%) and neurologic disorders (5%). The severity of adverse events was mainly at level 3. Conclusion: Adverse events identified in this study could be used in determining approaches for preventing and correcting complications from chemotherapy treatment in patients with hematologic malignancies.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. National Cancer Institute. Hospital based cancer registry annual report 2012 [online]. 2012 [cited 2016 Mar 2]. Available from: http://www.nci.go.th/ th/File_download/Nci%20Cancer%20Registry/Hospital-Based%20NCI%202012%20Total.pdf.
3. National Cancer Institute. Standard cancer treat- ment being used in Thailand [online]. 2008 [cited 2016 Mar 2]. Available from :http://www.nci.go.th/th /Knowledge/treat.html.
4. American Society of Clinical Oncology. Side effects of chemotherapy [online]. 2005 [cited 2016 March 2]. Available from: http://www.cancer.net/navigating -cancer-care/how-cancer-treated/chemotherapy/ side-effects-chemotherapy.
5. Cancer Research UK. Chemotherapy and side effects for non-Hodgkin lymphoma [online]. 2014 [cited 2016 March 2]. Available from: http//www. cancerresearchuk.org/about-cancer/type/non-hodg kins-lymphoma/treatment/chemotherapy/chemothe rapy-and-side-effects-for-non-hodgkins-lymphoma.
6. Karpa KD, Lewis PR, Felix TM. Adverse effects of common drugs: general concepts. FP Essent 2015; 436: 11-6.
7. Alhomoud F, Dhillon S, Aslanpour Z, Smith F. Medicine use and medicine-related problems experienced by ethnic minority patients in the United Kingdom: a review. Int J Pharm Pract 2013 ; 21: 277-87.
8. Woopen H, Richter R, Ismaeel F, Chekerov R, Roots I, Siepmann T, et al. The influence of polypharmacy on grade III/IV toxicity, prior discon- tinuation of chemotherapy and overall survival in ovarian cancer. Gynecol Oncol 2016; 140: 554-8.
9. Kierner KA, Weixler D, Masel EK, Gartner V, Watzke HH. Polypharmacy in the terminal stage of cancer. Support Care Cancer 2016; 24: 2067-74.
10. Chindaprasirt J, Wanitpongpun C, Limpawattana P, Thepsuthammarat K, Sripakdee W, Sookprasert A, et al. Mortality, length of stay, and cost associated with adult cancer patients with febrile neutropenia. Asian Pac J Cancer Prev 2013; 14: 1115-9.
11. Ob-oun T, Kopol J, Phosahut P, Thirasirawate S, Chisong C, Phumart P, et al. Adverse drug reac- tion monitoring and counseling in oncologic patients at Mahasarakham hospital. Paper presented at: The 4th Annual Pharmacy Research Conference of 2012 “Pharmacy Profession in Harmaony”; 2012 Feb 11-12; Khon Kaen, Thailand.
12. Saransate R, Soorapan S, Pattharachayakul S, Pratheepawanit N. Effects of pharmacist counsel- ing for lymphoma patients at Songklanagarind Hospital: a randomized controlled trial. Songkla Med J 2006; 24: 407-17.
13. Sonklanakarind hospital. Hospital-based cancer registry Sonklanagarind hospital annual report 2013 [online]. 2013 [2016 Mar 17]. Available from: URL:http://medinfo2.psu.ac.th/cancer/data/tumor_registry_ 2013.pdf
14. World Health Organization. International monitoring of adverse reactions to drugs: adverse reaction terminology [online]. 1992 [cited 2016 Mar 2]. Available from: http//www.who.int/medicines/areas/quality_safety/safety_efficacy/trainingcourses/ definitions.pdf.
15. National Institutes of Health National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0 [online]. 2009 [cited 2013 May 10]. Available from: http://evs.nci.nih.gov /ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickRefe rence_5x7.pdf.
16. Abro UE, Morris K, Hodges G, Butler JP, Curley C, Pillai ES, et al. Outpatient administration of Hyper-CVAD chemotherapy for acute lympho blastic leukaemia/lymphoma is safe and associated with similar toxicity compared to inpatient delivery. Blood 2013; 122: 5017.
17. Shi W, Shi YK, He XH, Zhou SY, Dong M, Zhang CG, et al. A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma. Zhonghua Yi Xue Za Zhi 2010; 90: 978 -81.
18. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensi- fication in acute myeloid leukemia. N Engl J Med 2009; 361:1249-59.
